⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179391 | 1.00 | — | — | |
| SCHEMBL12334740 | 0.85 | GBA1 (0.55) | — | |
| SCHEMBL10082058 | 0.85 | GBA1 (0.55) | — | |
| SCHEMBL403895 | 0.85 | GBA1 (0.55) | — | |
| SCHEMBL26268116 | 0.85 | GBA1 (0.55) | — | |
| SCHEMBL6335676 | 0.83 | GABRR1 (0.43) | — | |
| SCHEMBL4445650 | 0.83 | GABRR1 (0.43) | — | |
| SCHEMBL2811192 | 0.83 | GABRR1 (0.43) | — | |
| SCHEMBL22160590 | 0.83 | GABRR1 (0.43) | — | |
| SCHEMBL13221050 | 0.83 | GABRR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613311-A | High-selectivity synthesis method of (3S, 4R) -3- (N-benzyl-N-cyclopropyl) aminomethyl-4-hydroxypyrrolidine-1-carboxylic acid benzyl ester | 武汉理工大学 | 2025-03-14 | — | — | CN | claimed |
| EP-1992613-B1 | PROCESS FOR PRODUCTION OF 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND INTERMEDIATE FOR THE PRODUCTION | KYORIN SEIYAKU KK (JP) | 2013-01-30 | — | — | EP | claimed |
| US-8084622-B2 | stereoselective asymmetric hydrogenation of 1-protected-4-alkoxycarbonyl-3-oxopyrrolidine, followed by ester hydrolysis, followed by amidation with cyclopropylamine; production of (3R,4S)-3-cyclopropylaminomethyl-4-fluoropyrrolidine useful as an intermediate to novel antibiotics | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | claimed |
| US-20100056805-A1 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | GOTOH TAKAYUKI | 2010-03-04 | — | — | US | claimed |
| US-7667049-B2 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-23 | — | — | US | claimed |
| US-20090023935-A1 | Process for Producing 3,4-Disubstituted Pyrrolidine Derivative and Production Intermediate Thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-22 | — | — | US | claimed |
| EP-1992613-A1 | PROCESS FOR PRODUCTION OF 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND INTERMEDIATE FOR THE PRODUCTION | Kyorin Pharmaceutical Co., Ltd. (JP) | 2008-11-19 | — | — | EP | claimed |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-10385055-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3400228-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
| EP-1992613-B1 | PROCESS FOR PRODUCTION OF 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND INTERMEDIATE FOR THE PRODUCTION | KYORIN SEIYAKU KK (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-8084622-B2 | stereoselective asymmetric hydrogenation of 1-protected-4-alkoxycarbonyl-3-oxopyrrolidine, followed by ester hydrolysis, followed by amidation with cyclopropylamine; production of (3R,4S)-3-cyclopropylaminomethyl-4-fluoropyrrolidine useful as an intermediate to novel antibiotics | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20100056805-A1 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | GOTOH TAKAYUKI | 2010-03-04 | — | — | US | disclosed |
| US-7667049-B2 | Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090023935-A1 | Process for Producing 3,4-Disubstituted Pyrrolidine Derivative and Production Intermediate Thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1992613-A1 | PROCESS FOR PRODUCTION OF 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND INTERMEDIATE FOR THE PRODUCTION | Kyorin Pharmaceutical Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |